Short Interest in SciSparc Ltd. (NASDAQ:SPRC) Expands By 411.9%

SciSparc Ltd. (NASDAQ:SPRC) saw a large increase in short interest in January. As of January 15th, there was short interest totalling 795,500 shares, an increase of 411.9% from the December 31st total of 155,400 shares. Approximately 7.7% of the shares of the stock are short sold. Based on an average trading volume of 7,930,000 shares, the short-interest ratio is presently 0.1 days.

SciSparc Stock Down 9.5 %

SciSparc stock traded down $0.05 during midday trading on Wednesday, hitting $0.48. The stock had a trading volume of 392,754 shares, compared to its average volume of 13,128,630. The business has a fifty day moving average price of $0.42 and a 200 day moving average price of $0.36. SciSparc has a 12 month low of $0.20 and a 12 month high of $6.78.

Hedge Funds Weigh In On SciSparc

A hedge fund recently bought a new stake in SciSparc stock. Renaissance Technologies LLC bought a new position in SciSparc Ltd. (NASDAQ:SPRC) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 39,700 shares of the company’s stock, valued at approximately $32,000. Renaissance Technologies LLC owned 5.59% of SciSparc at the end of the most recent quarter. Institutional investors and hedge funds own 25.06% of the company’s stock.

SciSparc Company Profile

SciSparc Ltd., a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies. Its drug development programs include SCI-110 for the treatment of Tourette syndrome and Alzheimer's disease and agitation; SCI-160 for the treatment of pain; SCI-210 for the treatment of autism spectrum disorder and status epilepticus; and CannAmide, an anti-inflammatory and chronic pain solution.